TD Cowen initiated coverage of Zymeworks (ZYME) with a Buy rating and no price target The company has a “differentiated platform” of antibody drug conjugates and multi-specific T cell engagers across oncology and autoimmune and inflammatory disease, the analyst tells investors in a research note. The firm believes Ziihera has blockbuster potential and impending data will be the next key catalyst for the stock in the second half of 2025. Royalties from Ziihera should fund Zymeworks’ pipeline in the next two years, contends TD.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment
- Zymeworks presents new ZW1528 data at ATS conference
- Zymeworks’s Promising Pipeline and Strategic Partnerships Drive Buy Rating
- Zymeworks Earnings Call Highlights Growth and Partnerships
- Zymeworks Reports Q1 2025 Financial Results and R&D Progress